









Markets
/
Stocks
/
nasdaq-cris
/

Curis Inc

CRIS

0.516USD

-0.064-10.95%

Close 03/30, 16:00（ET）Quotes delayed by 15 min

406.39KMarket Cap

LossP/E TTM



Curis Inc

0.516

-0.064-10.95%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Curis Inc

Currency: USD Updated: 2026-03-27

Key Insights

Curis Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 138 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Curis Inc's Score

Industry at a Glance

Industry Ranking

138 / 391

Overall Ranking

260 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Curis Inc Highlights

StrengthsRisks

Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.

Growing

The company is in a growing phase, with the latest annual income totaling USD 9.44M.

Fairly Valued

The company’s latest PE is -0.96, at a medium 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 240.92K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.33.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

14.000

Target Price

+2313.79%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Curis Inc is 7.69, ranking 70 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 1.14M, representing a year-over-year decrease of 65.98%, while its net profit experienced a year-over-year decrease of 301.25%.

Score

Industry at a Glance

Previous score

7.69

Change



Financials

5.17

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.55

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.35

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.36

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Curis Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Curis Inc is 6.80, ranking 217 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.96, which is -80.21% below the recent high of -0.19 and -102.13% above the recent low of -1.95.

Score

Industry at a Glance

Previous score

6.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 138/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Curis Inc is 8.00, ranking 163 out of 391 in the Biotechnology & Medical Research industry. The average price target is 17.00, with a high of 20.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

14.000

Target Price

+2420.25%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Curis Inc

CRIS

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Curis Inc is 5.28, ranking 320 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.95 and the support level at 0.34, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.14

Change

0.14

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.075

Sell

RSI(14)

21.268

Sell

STOCH(KDJ)(9,3,3)

6.512

Oversold

ATR(14)

0.084

Low Volatility

CCI(14)

-139.662

Sell

Williams %R

94.268

Oversold

TRIX(12,20)

-1.472

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.658

Sell

MA10

0.738

Sell

MA20

0.875

Sell

MA50

0.951

Sell

MA100

1.056

Sell

MA200

1.415

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Curis Inc is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 39.24%, representing a quarter-over-quarter decrease of 1.51%. The largest institutional shareholder is The Vanguard, holding a total of 366.11K shares, representing 2.67% of shares outstanding, with 8.02% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Bleichroeder LP

1.14M

+9.66%

Satterfield (Thomas A Jr)

886.71K

+44.84%

Armistice Capital LLC

978.19K

+8.70%

M28 Capital Management LP

521.06K

The Vanguard Group, Inc.

Star Investors

367.62K

+21.25%

CM Management, LLC

325.00K

+47.73%

Renaissance Technologies LLC

Star Investors

175.51K

+74.69%

Citi Investment Research (US)

581.12K

+532.53%

Geode Capital Management, L.L.C.

94.67K

+10.98%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Curis Inc is 1.96, ranking 260 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 3.04. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.